Efficacy, Safety and Cost of Regorafenib in Patients with Metastatic Colorectal Cancer in French Clinical Practice

Efficacy, Safety and Cost of Regorafenib in Patients with Metastatic Colorectal Cancer in French Clinical Practice

Show other versions (1)

Bibliographic Details
Main Authors:	Fabien Calcagno, Sabrina Lenoble, Zaher Lakkis, Thierry Nguyen, Samuel Limat, Christophe Borg, Marine Jary, Stefano Kim, Virginie Nerich
Format:	Article
Language:	English
Published:	SAGE Publishing 2016-07-01
Series:	Clinical Medicine Insights: Oncology
Online Access:	http://www.la-press.com/efficacy-safety-and-cost-of-regorafenib-in-patients-with-metastatic-co-article-a5743

Similar Items

Efficacy, Safety and Cost of Regorafenib in Patients with Metastatic Colorectal Cancer in French Clinical Practice
by: Fabien Calcagno, et al.
Published: (2016-01-01)

The role of regorafenib in the treatment of metastatic colorectal cancer
by: A A Tryakin
Published: (2016-06-01)

Monitoring levels of circulating cell‐free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatment
by: Brice Pastor, et al.
Published: (2021-09-01)

Practical considerations in the use of regorafenib in metastatic colorectal cancer
by: Fotios Loupakis, et al.
Published: (2020-10-01)

Meeting An Unmet Need in Metastatic Colorectal Carcinoma with Regorafenib
by: Barbara Melosky
Published: (2016-01-01)

Factors Associated With Regorafenib Adherence With Metastatic Colorectal Cancer
by: Kawakami K, et al.
Published: (2019-10-01)

Practice patterns and outcomes with the use of regorafenib in metastatic colorectal cancer: Results from the Regorafenib in Metastatic colorectal cancer - An Indian exploratory analysis study
by: Anant Ramaswamy, et al.
Published: (2019-01-01)

Using of multi-kinase inhibitor regorafenib for metastatic colorectal cancer
by: O I Kit, et al.
Published: (2017-06-01)

Regorafenib application in patients with metastatic colorectal cancer in actual clinical practice
by: M I Sekacheva, et al.
Published: (2016-09-01)

Clinical Implication of Anti-Angiogenic Effect of Regorafenib in Metastatic Colorectal Cancer.
by: Yoojoo Lim, et al.
Published: (2015-01-01)

The use of regorafenib for patients with refractory metastatic colorectal cancer in clinical practice
by: Yoon SE, et al.
Published: (2018-12-01)

Modern perspectives in sequential therapy for metastatic colorectal cancer with reference to the use of regorafenib
by: M. I. Sekacheva, et al.
Published: (2020-11-01)

Efficacy of Regorafenib in Metastatic Colorectal Cancer: A Multi-institutional Retrospective Study
by: Ali Aljubran, et al.
Published: (2019-01-01)

Proactive strategies for regorafenib in metastatic colorectal cancer: implications for optimal patient management
by: Khan G, et al.
Published: (2014-03-01)

Metastatic colorectal cancer responsive to regorafenib for 2 years: a case report
by: Kenji Yoshino, et al.
Published: (2017-08-01)

The use of regorafenib in colorectal cancer
by: Marina I Sekacheva, et al.
Published: (2019-06-01)

Hospitalizations and Clinical Outcome in Metastatic Colorectal Cancer During Regorafenib or TAS-102 Therapy
by: Florian Huemer, et al.
Published: (2020-09-01)

Regorafenib for Metastatic Colorectal Cancer: An Analysis of a Registry-Based Cohort of 555 Patients
by: Novakova-Jiresova A, et al.
Published: (2020-07-01)

Durable response using regorafenib in an elderly patient with metastatic colorectal cancer: case report
by: Tang R, et al.
Published: (2015-11-01)

RECIST and CHOI criteria in the evaluation of tumor response in patients with metastatic colorectal cancer treated with regorafenib, a prospective multicenter study
by: Olivier Lucidarme, et al.
Published: (2019-12-01)

Combination chemotherapy with Regorafenib in metastatic colorectal cancer treatment: A single center, retrospective study.
by: Chun-Yu Lin, et al.
Published: (2018-01-01)

Oncologic Outcomes in Metastatic Colorectal Cancer with Regorafenib with FOLFIRI as a Third- or Fourth-Line Setting
by: Cheng-Jen Ma, et al.
Published: (2019-03-01)

Real-world evidence of the safety and effectiveness of regorafenib in Taiwanese patients with metastatic colorectal cancer: CORRELATE Taiwan
by: Kun-Huei Yeh, et al.
Published: (2021-11-01)

Peripheral Innate Lymphoid Cells Are Increased in First Line Metastatic Colorectal Carcinoma Patients: A Negative Correlation With Th1 Immune Responses
by: Romain Loyon, et al.
Published: (2019-09-01)

A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancer.
by: Yuji Miyamoto, et al.
Published: (2020-01-01)

Treatment Outcomes of Metastatic Colorectal Cancer Patients Treated with Regorafenib as Third-Line Setting-A Multicenter Study
by: Süleyman Şahin, et al.
Published: (2019-03-01)

Biomarkers Associated with Regorafenib First-Line Treatment Benefits in Metastatic Colorectal Cancer Patients: REFRAME Molecular Study
by: Elisa Conde, et al.
Published: (2021-04-01)

Efficacy of A Fluoropyrimidine plus Mitomycin C in Pretreated Patients with Metastatic Colorectal Cancer Eligible for Regorafenib: A Retrospective Study
by: Federica Martorana, et al.
Published: (2017-11-01)

Molecular profiling in the treatment of colorectal cancer: focus on regorafenib
by: Yan Y, et al.
Published: (2015-10-01)

Critical appraisal of the use of regorafenib in the management of colorectal cancer
by: Festino L, et al.
Published: (2013-04-01)

Role of KRAS mutations in patients with metastatic colorectal cancer who receive regorafenib plus FOLFIRI as a salvage therapy
by: Tsung-Kun Chang, et al.
Published: (2018)

Effect of starting dose of regorafenib on overall survival of patients with metastatic colorectal cancer: a systematic review and meta-analysis
by: Mikhail Yu Fedyanin, et al.
Published: (2019-09-01)

High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib
by: Alessio Amatu, et al.
Published: (2019-07-01)

Regorafenib Enhances Lethality of Sildenafil and Curcumin in Colorectal Cancer Cells
by: Owusu, Kervin Benjamin
Published: (2019)

Long-Term Survival with Regorafenib in KRAS-Mutated Metastatic Rectal Cancer
by: Marie-Laure Amram, et al.
Published: (2017-11-01)

Regorafenib plus toripalimab in patients with metastatic colorectal cancer: a phase Ib/II clinical trial and gut microbiome analysis
by: Feng Wang, et al.
Published: (2021-09-01)

Impact of tumour growth rate during preceding treatment on tumour response to regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer
by: Toshiki Masuishi, et al.
Published: (2019-11-01)

Clinical Impact of Primary Tumor Location in Metastatic Colorectal Cancer Patients Under Later-Line Regorafenib or Trifluridine/Tipiracil Treatment
by: Hiromichi Nakajima, et al.
Published: (2021-06-01)

Regorafenib vs trifluridine/tipiracil for metastatic colorectal cancer refractory to standard chemotherapies: A multicenter retrospective comparison study in Japan.
by: Misato Ogata, et al.
Published: (2020-01-01)

Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study
by: Faysal Dane, et al.
Published: (2020-03-01)

Cannot write session to /tmp/vufind_sessions/sess_rc1ilcj8q55uqnlcbrik1892q5